Welcome to Vivet Therapeutics
Vivet Therapeutics is dedicated to developing innovative gene therapy treatments for orphan diseases.
Vivet Therapeutics is focused on optimizing gene therapy through collaborating with the Fundacion para la Investigacion Medica Aplicada (FIMA) at the Centro de Investigación Medica Aplicada (CIMA, Universidad de Navarra) to develop new AAV vectors specifically targeting the liver and generating new technologies to optimize gene delivery and long term expression.
Latest News
-
Vivet Therapeutics raises €37.5 million in Series A financing round
Vivet Therapeutics raises €37.5 million in Series A financing round to advance novel gene therapies for treating inherited metabolic diseases
-
Vivet Annual Meeting in Washington DC
Vivet Therapeutics Announces Presentation at the Upcoming American Society For Gene And Cell Therapy (ASGCT) Annual Meeting in Washington DC
-
FDA news : Cellular & Gene Therapy Guidances
A useful resource of Cellular & Gene Therapy Guidance Documents
-
EMA News
This section of the website provides information for companies and individuals involved in developing and marketing medicines for human use…
-
Gene Therapy of Liver Diseases
In Europe, a disease is defined as rare when it affects fewer than one out of every 2,000 people. However,…
